The next era of hepatitis C therapy could begin on Dec. 6, if FDA approves Gilead's sofosbuvir. Amarin is hoping FDA approves an expanded label for its prescription-grade fish oil pill Vascepa on Dec. 20.
Sarepta Therapeutics (SRPT) and Pharmacyclics (PCYC) aren't on the list but are still very much in the investor spotlight. Sarepta and FDA are still going back and forth over the the company's request to file an accelerated approval application for eteplirsen to treat Duchenne muscular dystrophy. We may have some resolution early in the third quarter.
Pharmacylics and partner Johnson & Johnson (JNJ) are expected to seek FDA approval for their blood-cancer drug ibrutinib before the end of the third quarter. FDA has already annointed ibrutinib with multiple breakthrough therapy designations, so it makes sense for the agency to approve the drug quickly. Is an ibrutinib approval before year end a possibility? I think so, in fact, I'd say the Street expects an early approval.Let's not forget the importance of European drug approvals. Here are the dates for the remaining Committee for Medicinal Products for Human Use (CHMP) meetings in 2013: May 27-30; June 24-27; July 22-25; Aug. 19-22; Sept. 16-19; Oct. 21-24; Nov. 18-2; and Dec. 16-19. The most closely watched, upcoming European drug approval decisions include Dendreon (DNDN) (Provenge, prostate cancer); Aegerion Pharmaceuticals (AEGR) (Juxtapid, homozygous familial hypercholesterolemia) and Celgene (CELG) (Pomalyst, multiple myeloma.) Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels. Merck (MRK)
Drug/indication: Suvorexant for insomnia
FDA advisory panel: May 22
Approval decision date: June-July Valeant Pharmaceuticals (VRX)
Drug/indication: Efinaconazole, toe-nail fungus
Approval decision date: May 23 Depomed (DEPO)
Drug/indication: Sefelsa, menopause
Approval decision date: May 31 Zogenix (ZGNX)
Drug/indication: Zohydro, chronic pain
Approval decision date: Summer GlaxoSmithKline (GSK)
Drug/indication: Dabrafenib, melanoma
Approval decision date: June 3 Aveo Pharmaceuticals (AVEO)
Drug/indication: Tivozanib, kidney cancer
Approval decision date: July 26
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV